T-cell responses to oncogenic Merkel cell polyomavirus proteins distinguish patients with Merkel cell carcinoma from healthy donors

Clinical Cancer Research

Volumn 20, Issue 7, 2014, Pages 1768-1778

  Lyngaa, Rikke ^a   Pedersen, Natasja Wulff ^a   Schrama, David ^b   Thrue, Charlotte Albkæ ^a   Ibrani, Dafina ^c,d   Met, Özcan ^a   Straten, Perthor ^a   Nghiem, Paul ^c,d   Becker, Jürgen C ^b   Hadrup, Sine Reker ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; ONCOPROTEIN; VIRUS LARGE T ANTIGEN; VIRUS PROTEIN; VIRUS SMALL T ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CANCER PATIENT; CARCINOGENICITY; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DISEASE ASSOCIATION; DONOR; HOST; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOTHERAPY; MERKEL CELL POLYOMAVIRUS; MERKEL CELL TUMOR; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; VIRUS CARCINOGENESIS; CARCINOGENESIS; CARCINOMA, MERKEL CELL; DIAGNOSTIC USE; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; ISOLATION AND PURIFICATION; PATHOGENICITY; PATHOLOGY; SKIN NEOPLASMS; T LYMPHOCYTE; VIROLOGY;

CARCINOGENESIS; CARCINOMA, MERKEL CELL; EPITOPES; HUMANS; IMMUNITY, INNATE; MERKEL CELL POLYOMAVIRUS; SKIN NEOPLASMS; T-LYMPHOCYTES; VIRAL PROTEINS;

EID: 84898750264     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2697     Document Type: Article

References (47)

1. Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 2010;63:751-61.
2. Friedlaender MM, Rubinger D, Rosenbaum E, Amir G, Siguencia E. Temporary regression of Merkel cell carcinoma metastases after cessation of cyclosporine. Transplantation 2002;73:1849-50. (Pubitemid 34655267)
3. Heath M, Jaimes N, Lemos B, Mostaghimi A, Wang LC, Peñas PF, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol 2008;58:375-81. (Pubitemid 351226308)
4. Paulson KG, Iyer JG, Tegeder AR, Thibodeau R, Schelter J, Koba S, et al. Transcriptome-wide studies of Merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol 2011;29:1539-46.
5. Rodig SJ, Cheng J, Wardzala J, Dorosario A, Scanlon JJ, Laga AC, et al. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest 2012;122:4645-53.
6. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008;319:1096-100. (Pubitemid 351300792)
7. Sastre-garau X, Peter M, Avril M-F, Laude H, Couturier J, Rozenberg F, et al. Merkel cell carcinoma of the skin: pathological and molecular evidence for a causative role of MCV in oncogenesis. J Pathol 2009;218:48-56.
8. Laude HC, Jonchère B, Maubec E, Carlotti A, Marinho E, Couturaud B, et al. Distinct Merkel cell polyomavirus molecular features in tumour and non tumour specimens from patients with Merkel cell carcinoma. PLoS Pathogen 2010;6:e1001076.
9. Martel-Jantin C, Filippone C, Cassar O, Peter M, Tomasic G, Vielh P, et al. Genetic variability and integration of Merkel cell polyomavirus in Merkel cell carcinoma. J Virol 2012;426:134-42.
10. Shuda M, Feng H, Kwun HJ, Rosen ST, Gjoerup O, Moore PS, et al. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci USA 2008;105:16272-7.
11. Shuda M, Kwun HJ, Feng H, Chang Y, Moore PS. Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. J Clin Invest 2011;121:3623-34.
12. Houben R, Shuda M, Weinkam R, Schrama D, Feng H, Chang Y, et al. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol 2010;84:7064-72.
13. Houben R, Adam C, Baeurle A, Hesbacher S, Grimm J, Angermeyer S, et al. An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells. Int J Cancer 2012;130:847-56.
14. Pastrana D V, Tolstov YL, Becker JC, Moore PS, Chang Y, Buck CB. Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathogens 2009;5:e1000578.
15. Chen T, Hedman L, Mattila PS, Jartti T, Ruuskanen O, Söderlund- Venermo M, et al. Serological evidence of Merkel cell polyomavirus primary infections in childhood. J Clin Virol 2011;50:125-9
16. Paulson KG, Carter JJ, Johnson LG, Cahill KW, Iyer JG, Schrama D, et al. Antibodies to Merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in Merkel cell carcinoma patients. Cancer Res 2010;70:8388-97.
17. + T-cell responses identified in Merkel cell carcinomas and blood Clin Cancer Res 2011;17:6671-80.
18. Hadrup SR, Bakker AH, Shu CJ, Andersen RS, van Veluw J, Hombrink P, et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Method 2009;6:520-6.
19. Andersen RS, Kvistborg P, Frøsig TM, Pedersen NW, Lyngaa R, Bakker AH, et al. Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nat Protoc 2012;7:891-902.
20. Hadrup SR, Schumacher TN. MHC-based detection of antigen-specific CD8+ T cell responses. Cancer Immunol Immunother 2010;59:1425-33.
21. Andersen RS, Thrue CA, Junker N, Lyngaa R, Donia M, Ellebæk E, et al. Dissection of T-cell antigen specificity in human melanoma. Cancer Res 2012;72:1642-50.
22. Rodenko B, Toebes M, Hadrup SR, van Esch WJE, Molenaar AM, Schumacher TNM, et al. Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc. 2006;1:1120-32.
23. Hadrup SR, Toebes M, Rodenko B, Bakker AH, Egan DA, Ovaa H, et al. High-throughput T-cell epitope discovery through MHC peptide exchange. Methods Mol Bio 2009;524:383-405.
24. Bakker AH, Hoppes R, Linnemann C, Toebes M, Rodenko B, Berkers CR, et al. Conditional MHC class I ligands and peptide exchange technology for the humanMHCgene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci USA 2008;105:3825-30. (Pubitemid 351723484)
25. Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ, et al. Design and use of conditional MHC class I ligands. Nat Med 2006;12:246-51. (Pubitemid 43214754)
26. Stanke J, Hoffmann C, Erben U, von Keyserling H, Stevanovic S, Cichon G, et al. A flow cytometry-based assay to assess minute frequencies of CD8+ T cells by their cytolytic function. J Immunol Methods 2010;360:56-65.
27. Rammensee H, Bachmann J, Emmerich NP, Bachor OA SS. SYF-PEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50:213-9. (Pubitemid 30099526)
28. Lundegaard C, Lund O, Nielsen M. Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics 2008;24:1397-8. (Pubitemid 351737147)
29. Hombrink P, Hadrup SR, Bakker A, Kester MGD, Falkenburg JHF, von dem Borne PA, et al. High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations. PloS One 2011;6:e22523.
30. Houben R, Grimm J, Willmes C, Weinkam R, Becker JC, Schrama D. Merkel cell carcinoma and Merkel cell polyomavirus: evidence for hit-and-run oncogenesis. J Dermatol Sci 2012;132:254-6.
31. Becker JC, Andersen MH, Schrama D, Thor Straten P. Immunesuppressive properties of the tumor microenvironment. Cancer Immunol Immunother. 2013;62:1137-48.
32. Gotch F, McMichael A, Rothbard J. Recognition of influenza A matrix protein by HLA-A2-restricted cytotoxic T lymphocytes. Use of analogues to orientate the matrix peptide in the HLA-A2 binding site. J Exp Med 1988;168:2045-57. (Pubitemid 19020888)
33. Spurgeon ME, Lambert PF. Merkel cell polyomavirus: a newly discovered human virus with oncogenic potential. J Virol 2013;435:118-30.
34. DeCaprio JA, Garcea RL. A cornucopia of human polyomaviruses. Nat Rev Microbiol 2013;11:264-76.
35. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009;21:233-40.
36. Ellebaek E, Iversen TZ, Junker N, Donia M, Engell-Noerregaard L, Met Ö, et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose interleukin-2 in metastatic melanoma patients. J Trans Med 2012;10:169.
37. Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
38. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 2012;18:6758-70.
39. Paulson KG, Iyer JG, Blom A, Warton EM, Sokil M, Yelistratova L, et al. Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J Invest Dermatol 2013;133:642-6.
40. Touzé A, Le Bidre E, Laude H, Fleury MJJ, Cazal R, Arnold F, et al. High levels of antibodies against Merkel cell polyomavirus identify a subset of patients with Merkel cell carcinoma with better clinical outcome. J Clin Invest 2011;29:1612-9.
41. Jelcic I, Aly L, Binder TMC, Jelcic I, Bofill-Mas S, Planas R, et al. T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors. J Virol 2013;87:3393-408.
42. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
43. Dowlatshahi M, Huang V, Gehad AE, Jiang Y, Calarese A, Teague JE, et al. Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses. J Invest Dermatol 2013;133:1879-89.
44. Afanasiev OK, Yelistratova L, Miller N, Nagase K, Paulson K, Iyer J, et al. Merkel polyomavirus-specific T cells fluctuate with Merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res 2013;19:5351-60.
45. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
46. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
47. List T, Neri D. Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol 2013;5:29-45.